HIV/AIDS Reports
HIV/AIDS Market Size and Performance - Current Market Reports
BioPortfolio.net provides a wide range of reports on the HIV/AIDS market including treatment reviews and diagnostic technology reviews
Latest HIV/AIDS Market Research Reports
BioPortfolio lists the most up to date HIV/AIDS market reports from over 30 leading market research companies for immediate purchase using our SECURE payment system. You can buy the latest HIV/AIDS reports immediately online now.
BioPortfolio lists the most up-to-date HIV/AIDS market reports from over 30 of the world's leading market research companies for immediate purchase using our SECURE payment system. You can purchase the latest HIV/AIDS reports immediately online now.
Listed here are reports on market size as well as for the HIV/AIDS testing and treatment markets.
What is HIV/AIDS?
The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immunodeficiency Syndrome a condition wherin the gradual failure of the immune system causesd by the HIV pathogen allows diseases and cancers, with the potential to threaten life in humans, to thrive.
The progressive breakdown of the immune system is caused by the infection of vital cells within the human body, for example helper T-cells, macrophages and dendritic cells. This increases the chance for opportunistic infections to take hold.
Diagnosis
Testing for HIV is routinely carried out on blood samples prior to blood donation.
The method for testing for HIV-1 is as follows:
- Use of an enzyme-linked immunosorbent assay (ELISA) which detects antibodies used to fight HIV-1.
- If there is no reaction to the ELISA the specimin is considered to be HIV-negative unless they have been exposed to a partner of unknown or positive HIV status.
- Those with reactive samples and re-tested and re-tested again. If either sample is found to be reactive to the ELISA then they are sent for additional testing, for example Western Blot Testing.
- Those whose samples repeatedly show reactivity with ELISA and with the additional testing are considered to be HIV positive.
The accuracy of this testing method is very high, in excess of 99%
Current HIV/AIDS News
The latest HIV/AIDS news from around the world is also available on the HIV/AIDS news pages of our sister site BioPortfolio.com
Leading HIV/AIDS Market Research Reports
Here is our current list of market research reports about HIV/AIDS.
HIV Partnering 2007-2013 Edition: 1 Code: CP2206hiv published last year by Current Partnering …HIV Partnering 2007-2013 report provides understanding and access to the HIV partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in HIV partnering deals Top HIV deals by value Deals listed by company A-Z, industry sector, stage of development, technology type Description:The HIV Partnering 2007-2013 provides… | Buy nowMore info | |
AIDS Partnering 2007-2013 Edition: 1 Code: CP2224 published last year by Current Partnering …AIDS Partnering 2007-2013 report provides understanding and access to the AIDS partnering deals and agreements entered into by the worlds leading healthcare companiesDescription:The AIDS Partnering 2007-2013 report provides understanding and access to the AIDS partnering deals and agreements entered into by the worlds leading healthcare companies. •Trends in AIDS partnering… | Buy nowMore info | |
AIDS Partnering 2007-2012 published last year by Current Partnering …understanding and access to the AIDS partnering deals and agreements entered into by the worlds leading healthcare companies Description:The AIDS Partnering 2007-2012 report provides understanding and access to the AIDS partnering deals and agreements entered into by the worlds leading healthcare companies. •Trends in AIDS partnering deals •Top AIDS deals… | Buy nowMore info | |
HIV Partnering 2007-2012 published last year by Current Partnering …understanding and access to the HIV partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in HIV partnering deals Top HIV deals by value Deals listed by company A-Z, industry sector, stage of development, technology type Description:The HIV Partnering 2007-2012 provides understanding and access to the… | Buy nowMore info | |
Global HIV/AIDS Testing Market 2010–2014 published last year by Infiniti Research (Technavio) TechNavio’s analysts forecast the Global HIV/AIDS Testing market to grow at a CAGR of 5.2 percent over the period 2010–2014. One of the key factors contributing to this market growth is the steady rise in the number of people prone to HIV/AIDS. The Global HIV/AIDS Testing market has also been… | Buy nowMore info | |
Global HIV Drugs Market 2010-2014 published 7 Dec 2011 by Infiniti Research (Technavio) TechNavio’s analysts forecast the Global HIV Drugs market to reach US$15.5 billion by 2014. One of the key factors contributing to this market growth is the increase in the use of highly active antiretroviral therapy. The Global HIV Drugs market has also been witnessing the need for novel HIV drugs… | Buy nowMore info | |
HIV Drugs Market in India 2010-2014 published 6 Nov 2011 by Infiniti Research (Technavio) TechNavio’s analysts forecast the HIV Drugs market in India to reach US$54 million by 2014. One of the key factors contributing to this market growth is the increasing prevalence of HIV in India and the longer life expectancy of HIV patients. The HIV Drugs market in India has also been… | Buy nowMore info | |
Complera (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Complera (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Atripla (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Atripla (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Quad 2 (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Quad 2 (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a… | Buy nowMore info | |
Stribild (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Stribild (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Dolutegravir (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Dolutegravir (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
572-Trii (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “572-Trii (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Cobicistat (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Cobicistat (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Elvitegravir (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Elvitegravir (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Isentress (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Isentress (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Prezista (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Prezista (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Norvir (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Norvir (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Kaletra (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Kaletra (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Reyataz (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Reyataz (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Truvada (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Truvada (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
Epzicom (HIV) - Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new PharmaPoint Drug Evaluation report, “Epzicom (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
PharmaPoint: HIV - China Drug Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new Country report, “PharmaPoint: HIV - China Drug Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
PharmaPoint: HIV - Italy Drug Forecast and Market Analysis to 2022 published this year by GlobalData …has released its new Country report, “PharmaPoint: HIV - Italy Drug Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly… | Buy nowMore info | |
HIV-1 Infection – Pipeline Review, H1 2013 published this year by Global Markets Direct …of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for HIV-1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-1 Infection. HIV-1 Infection - Pipeline Review, Half Year is built… | Buy nowMore info |